Literature DB >> 10561522

Does myasthenia gravis affect the brain?

J C Keesey1.   

Abstract

Associations between myasthenia gravis (MG) and CNS functions have been made for over 80 years. An increased incidence of psychiatric disorders, epilepsy and multiple sclerosis as well as electroencephalographic (EEG) abnormalities and abnormal evoked responses have been noted in patients with MG. Descriptions of sleep and memory disturbances in MG patients appeared as knowledge accumulated about the role of brain cholinergic systems in sleep and memory. The inference of many of these studies has been that the alleged central cholinergic effects in MG were caused either by the anticholinesterases used to treat MG or by antibodies to muscle nicotinic acetylcholine receptor (nAchR) present in the serum and cerebrospinal fluid (CSF) of MG patients. The antigenic differences between muscle nAchR and neuronal nAchRs, together with the very low concentrations of muscle nAchR antibodies in the CSF, make highly unlikely the claims that CNS cholinergic systems are affected by these muscle antibodies in MG patients. Evoked response abnormalities, if indeed present, are more likely caused by peripheral than central mechanisms, and sleep abnormalities in MG also probably originate in the periphery rather than in the CNS, the result of hypoxia caused by oropharyngeal, intercostal and diaphragmatic muscle weakness which may worsen during sleep, especially during REM sleep. Such hypoxia may account for some of the EEG abnormalities noted in MG patients, but the association of MG with epilepsy appears to be either coincidental or the result of uncontrolled MG. Significant excessive daytime sleepiness resulting from sleep disturbances can also impair memory and the performance of MG patients on neuropsychological tests, as can the presence of mental depression. The psychological aspects of MG can be attributed to the expected consequences of a chronic but unpredictable neuromuscular disease involving weakness of breathing, swallowing, talking, limb and eye movement. Considering the number and variety of claims for direct CNS involvement in MG, the evidence for this is remarkably unconvincing. The quality of MG treatment, both physical and psychological, is a presently undefined variable which might help explain the diametrically opposed results which have been obtained in some of the studies reviewed. Adequate respiratory muscle strength during sleep is an often overlooked peripheral influence upon mental functioning and general well-being of MG patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10561522     DOI: 10.1016/s0022-510x(99)00205-1

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  16 in total

1.  Social, professional and neuropsychiatric outcomes in patients with myasthenia gravis.

Authors:  Bruno Kusznir Vitturi; Alexandre In Han Kim; Lucas Pari Mitre; Ada Pellegrinelli; Berenice Cataldo Oliveira Valerio
Journal:  Neurol Sci       Date:  2020-06-26       Impact factor: 3.307

2.  [Intelligence, attention, and memory in patients with myasthenia gravis].

Authors:  R Feldmann; R Kiefer; U Wiegard; S Evers; J Weglage
Journal:  Nervenarzt       Date:  2005-08       Impact factor: 1.214

3.  The Relationship of Symptoms of Anxiety and Depression with Disease Severity and Treatment Modality in Myasthenia Gravis: A Cross-sectional Study.

Authors:  Fikret Aysal; Oğuz Karamustafalioğlu; Başak Özçelik; Meltem Yilmaz; Nesrin Karamustafalioğlu; Hüseyin Yumrukçal; Onur Tankaya
Journal:  Noro Psikiyatr Ars       Date:  2013-12-01       Impact factor: 1.339

Review 4.  Neuromuscular disorders and sleep.

Authors:  Ibrahim Oztura; Christian Guilleminault
Journal:  Curr Neurol Neurosci Rep       Date:  2005-03       Impact factor: 5.081

Review 5.  Pain, Headache, and Other Non-motor Symptoms in Myasthenia Gravis.

Authors:  Olivia Tong; Leslie Delfiner; Steven Herskovitz
Journal:  Curr Pain Headache Rep       Date:  2018-05-03

6.  Neuropsychological assessment in myasthenia gravis.

Authors:  Emilia J Sitek; Małgorzata M Bilińska; Dariusz Wieczorek; Walenty M Nyka
Journal:  Neurol Sci       Date:  2009-01-16       Impact factor: 3.307

Review 7.  Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment.

Authors:  Isin Baral Kulaksizoglu
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

8.  Differential diagnosis of hallucinations in a patient with myasthenia gravis.

Authors:  Sami Ouanes; Yosr Hizem; Mouna Ben Djebara; Imen Kacem; Amina Gargouri; Riadh Gouider
Journal:  Innov Clin Neurosci       Date:  2013-09

Review 9.  Current management options in myasthenia gravis.

Authors:  Stephen Reddel
Journal:  Curr Allergy Asthma Rep       Date:  2007-07       Impact factor: 4.806

10.  Profound olfactory dysfunction in myasthenia gravis.

Authors:  Fidias E Leon-Sarmiento; Edgardo A Bayona; Jaime Bayona-Prieto; Allen Osman; Richard L Doty
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.